Where would I be without ivermectin? Capturing the benefits of community-directed treatment with ivermectin in Africa

Tropical Medicine and International Health

Volumn 16, Issue 5, 2011, Pages 608-621

  Okeibunor, Joseph C ^a   Amuyunzu Nyamongo, Mary ^b   Onyeneho, Nkechi G ^a   Tchounkeu, Yolande F L ^c   Manianga, Cele ^d   Kabali, Asaph T ^e   Leak, Stephen ^f  

^a UNIVERSITY OF NIGERIA   (Nigeria)

^b AIHD   (Kenya)

^c Research Foundation for Tropical Diseases and Environment   (Cameroon)

^d University of Kinshasha   (Congo)

^e MAKERERE UNIVERSITY   (Uganda)

^f African Programme for Onchocerciasis Control   (Burkina Faso)

Author keywords

Africa; African Programme for Onchocerciasis Control; Benefits; Community directed treatment with ivermectin; Ivermectin; Onchocerciasis; Treatment

Indexed keywords

IVERMECTIN;

DEMOGRAPHIC SURVEY; DRUG; HEALTH EDUCATION; IVERMECTIN; ONCHOCERCIASIS; PERCEPTION; QUESTIONNAIRE SURVEY;

ADULT; AFRICA; AGED; ARTICLE; DEMOGRAPHY; DISEASE PREDISPOSITION; FEMALE; HEALTH CARE PERSONNEL; HOUSEHOLD; HUMAN; INTERVIEW; LEADERSHIP; LENGTH OF STAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MARRIAGE; NIGERIA; ONCHOCERCIASIS; PEER GROUP; PERCEPTION; SCHOOL; SELF ESTEEM; STRUCTURED QUESTIONNAIRE; UGANDA; WORK CAPACITY;

ADOLESCENT; ADULT; AFRICA; AGE DISTRIBUTION; COMMUNITY HEALTH SERVICES; COST OF ILLNESS; EPIDEMIOLOGIC METHODS; FEMALE; FILARICIDES; HUMANS; IVERMECTIN; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MOTIVATION; ONCHOCERCIASIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; SEX DISTRIBUTION; SOCIOECONOMIC FACTORS; YOUNG ADULT;

AFRICA;

EID: 79954915350     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2011.02735.x     Document Type: Article

References (46)

1. Akogun OB, Audu Z, Weiss MG et al. (2001) Community-directed treatment of Onchocerciasis with Ivermectin in Takum, Nigeria. Tropical Medicine & International Health 6, 232-243.
2. Amazigo UV (1994) Detrimental effects of onchocerciasis on marriage age and breast-feeding. Tropical and Geographical Medicine 46(5), 322-325.
3. Amazigo UV (2008) The African programme for onchocerciasis control (APOC). Annals of Tropical Medicine and Parasitology 102 (Suppl. 1), S19-S22.
4. Amazigo UV & Obikeze DS (1991) Socio-Cultural Factors Associated with Prevalence and Intensity of Onchocerciasis and Onchodermatitis Among Adolescent Girls in Rural Nigeria. SET/TDR Project Report. World Health Organization, Geneva.
5. Amazigo UV, Obono OM, Dadzie KY et al. (2002) Monitoring community-directed treatment programmes for sustainability: lessons from the African programme for onchocerciasis control (APOC). Annals of Tropical Medicine and Parasitology 96 (Suppl. 1), S75-S92.
6. Amazigo UV, Nnoruka E, Maduka C, Bump J, Benton B & Seketeli A (2004) Ivermectin improves the skin condition and self-esteem of females with onchocerciasis: a report of two cases. Annals of Tropical Medicine and Parasitology 98(5), 533-537.
7. Amazigo UV, Okeibunor JC, Matovu V, Zouré H, Bump J & Seketeli A (2007) Performance of Predictors: evaluating sustainability in community directed projects of the African programme for onchocerciasis control. Social Science and Medicine 64(10), 2070-2082.
8. Anosike JC, Dozie INS, Ameh GI et al. (2007) The varied beneficial effects of ivermectin (Mectizan) treatment as observed within onchocerciasis foci in south-eastern Nigeria. Annals of Tropical Medicine and Parasitology 101, 593-600.
9. Bernard R (2006) Research methodology in anthropology: qualitative and quantitative approaches, 4th edn. Altamira Press, Walnut Creek, CA.
10. Borsboom GJJM, Boatin BA, Nagelkerke NJD et al. (2003) Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West Africa. Filaria Journal 2(1), 8.
11. Bowdy MA (1999). The Cue to behaviour change model: integration of the health belief model and the transtheoretical model. MA Thesis, University of Kentucky 1-98.
12. Brieger WR, Oshiname FO & Ososanya OO (1998) Stigma associated with onchocercal skin disease among those affected near the Ofiki and Oyan rivers in Western Nigeria. Social Science & Medicine 47(7), 841-852.
13. Brieger WR, Okeibunor JC, Abiose AO et al. (2007) Feasibility of measuring compliance to annual ivermectin treatment in the African programme for onchocerciasis control. Tropical Medicine & International Health 12(2), 260-268.
14. Clemmons L, Amazigo UV, Bissek AC et al. (2002) Gender issues in the community-directed treatment with ivermectin (CDTI) of the African programme for onchocerciasis control (APOC). Annals of Tropical Medicine and Parasitology 96 (Suppl. 1), 59-74.
15. Cramer JA & Pugh MJ (2005) The influence of insulin use on glycemic control: how well do adults follow prescriptions for insulin? Diabetes Care 28(1), 78-83.
16. Depoortere E, Guthmann JP, Presse J et al. (2005) Efficacy and effectiveness of the combination of sulfadoxine/pyrimethamine and a 3-day course of artesunate for the treatment of uncomplicated falciparum malaria in a refugee settlement in Zambia. Tropical Medicine & International Health 10(2), 139-145.
17. Diawara L, Traore MO, Badji A et al. (2009) Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLOs Neglected Tropical Diseases 3, e497.
18. Dimofu BL, Lubeji DK, Noma M, Seketeli A & Boussinesq M (2007) African programme for onchocerciasis control (APOC): sociological study in three foci of Central Africa before the implementation of treatments with ivermectin (Mectizan®). Transactions of the Royal Society of Tropical Medicine and Hygiene 101, 674-679.
19. Engelhard P, Humble G & Mest D (2005) Safety of Sculptra: a review of clinical trial data. Journal of Cutaneous Laser Therapy 7(3-4), 201-205.
20. Heukelbach J, Winter B, Wilcke T et al. (2004) Selective mass treatment with ivermectin to control intestinal helminthiases and parasitic skin diseases in a severely infected population. Bulletin of the World Health Organization 82, 563-571.
21. Homeida M, Braide E, Elhassan E et al. (2002) APOC's strategy of community-directed treatment with ivermectin (CDTI) and its potential for providing additional health services to the poorest populations. African programme for onchocerciasis control. Annals of Tropical Medicine and Parasitology 96 (Suppl. 1), S93-S104.
22. Ikeda N, Hasegawa T, Hasegawa T, Saito I & Saruta T (2006) Awareness of the Japanese society of hypertension guidelines for the management of hypertension (2000) and compliance to its recommendations: surveys in 2000 and 2004. Journal of Human Hypertension 20, 263-266.
23. Iliyasu Z, Kabir M, Abubakar IS, Babashani M & Zubair ZA (2005) Compliance to antiretroviral therapy among AIDS patients in Aminu Kano Teaching Hospital, Kano, Nigeria. Nigerian Medical Journal 14, 290-294.
24. IPSOR Medication Compliance and Persistence Special Interest Group (2005) Standardizing Definition of Terms. International Society for Pharmacoeconomics and Outcomes Research. (accessed 15 March 2006).
25. James AS, Campbell MK & Hudson MA (2002) Perceived barriers and benefits to colon cancer screening among African Americans in North Carolina: how does perception relate to screening behavior? Cancer Epidemiology, Biomarkers and Prevention 11, 529-534.
26. Lawrence G, Leafasia J, Seridan J, Hills S, Wate J et al. (2005) Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin. Bulletin of the World Health Organization 83, 34-42.
27. Miyamoto T, Kumagai T, Jones JA, Van Dyke TE & Nunn ME (2006) Compliance as a prognostic indicator: retrospective study of 505 patients treated and maintained for 15years. Journal of Periodontology 77(2), 223-232.
28. Molyneux DH, Hotez P & Fenwick A (2005) "Rapid-impact interventions": how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Medicine 2(11), e336.
29. Ndyomugyenyi R, Byamungu A & Korugyendo R (2009) Perceptions on onchocerciasis and ivermectin treatment in rural communities in Uganda: implications for long-term compliance. International Health 1(2), 163-168.
30. Okeibunor JC, Ogungbemi MK, Sama M, Gbeleou SC, Oyene U & Remme JHF (2004) Additional health and development activities for community-directed distributors of ivermectin: threat or opportunity for onchocerciasis control? Tropical Medicine & International Health 9(8), 887d-896d.
31. Okeibunor JC, Abiose A, Onwujekwe OE et al. (2005) Rapid monitoring of ivermectin distribution: will school-based surveys provide the answer? Annals of Tropical Medicine 99(8), 771-780.
32. Pulliam C, Gatchel RJ & Robinson RC (2003) Challenges to early prevention and intervention: personal experiences with adherence. Clinical Journal of Pain 19(2), 114-120.
33. Ragot S, Sosner P, Bouche G, Guillemain J & Herpin D (2005) Appraisal of the knowledge of hypertensive patients and assessment of the role of the pharmacists in the management of hypertension: results of a regional survey. Journal of Human Hypertension 19(7), 577-584.
34. Remme JHF (2004) Research for control: the onchocerciasis experience. Tropical Medicine & International Health 9(2), 243-254.
35. Rosenstock IM (1974). Historical origin of the health belief model. Health Education Monograph 2, 328-335.
36. Rubio M, Pedeboscq S, Ekouevi D et al. (2005) The adherence to antiretroviral treatment evaluated from a hospital pharmacy: importance of the protease inhibitors pharmacological class. International Journal of STD and AIDS 16(5), 379-382.
37. Stone VE (2005) Physician contributions to disparities in HIV/AIDS Care: the role of provider perceptions regarding adherence. Current HIV/AIDS Reports 2(4), 189-193.
38. Sylla M, Kobylinski KC, Gray M et al. (2010) Mass drug administration of ivermectin in south-eastern Senegal reduces the survivorship of wild-caught, blood fed malaria vectors. Malaria Journal 9, 365-402.
39. TDR (2002) TDR Strategic Direction: Onchocerciasis. TDR, WHO, Geneva.
40. TDR (2004) Making Research Work for Poor People. Seventeenth Programme Report, Progress 2003-2004. TDR, Geneva.
41. Tielsch JM & Beeche A (2004) Impact of ivermectin on illness and disability associated with onchocerciasis. Tropical Medicine & International Health 9(4), A45-A56.
42. Trotta MP, Ammassari A, Melzi S et al. (2002) Treatment-related factors and highly active antiretroviral therapy adherence. Journal of Acquired Immune Deficiency Syndromes 15 (31 Suppl. 3), S128-S131.
43. Tsalikis G (1993) The onchocerciasis control programme (OCP) in West Africa: a review of progress. Health Policy and Planning 8, 349-359.
44. Weiden PJ & Rao N (2005) Teaching medication compliance to psychiatric residents: placing an orphan topic into a training curriculum. Academic Psychiatry 29(2), 203-210.
45. Weiss M, Vered I, Foldes AJ et al. (2005) Treatment preference and tolerability with alendronate once weekly over a 3-month period: An israeli multi-center study. Aging Clinical and Experimental Research 17(2), 143-149.
46. Yuan Y, L'italien G, Mukherjee J & Iloeje U (2006) Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Medicine 7(3), 156-162.